Governance

Hugel strengthens trust with all stakeholders by maintaining transparent governance and actively seeking to enhance corporate value.

Board of Directors

Hugel practices "board-centric management" to improve corporate and shareholder value. Renowned for their independence, expertise, and diversity, the board of directors at Hugel supports rational and transparent decision-making for the management.

Independence, Expertise, and Diversity of the Board of Directors

To reinforce the autonomy of board operations and enhance the transparency of supervisory duties, Hugel's board of directors made the decision in July 2022 to separate the roles of CEO and chairman of the board. Internal directors, each experts in their respective domains, take charge of managing different facets of the business.

Composition of Board of Directors

The Board of Directors of Hugel consists of 7 directors, including 5 non-executive directors and 2 independent directors as of end of March 2024. The board of directors deliberates on matters stipulated by laws or articles of incorporation, matters delegated by the shareholders' meeting, and important matters regarding the basic policies and execution of business management. The board also ensures institutional mechanisms for rational decision-making and transparency in management.

Board of Directors

Title
Name
POSITION
Term
TITLE
NAME · POSITION · TERM
Non-executive Director
Suk-yong Cha
Chair of the Board of Directors, Non-executive Director
23.03~26.03
Non-executive Director
Suhhong Hur
Non-executive Director
22.04~25.04
Non-executive Director
Michael Keyoung
Non-executive Director
22.04~25.04
Non-executive Director
Ki Chul Cho
Non-executive Director
24.03~27.03
Independent Director
Seungmin Chee
Chair of the Audit Committee 
Independent Director
22.04~25.04
Non-executive Director
Taehyoung Lee
Member of the Audit Committee
Non-executive Director
22.04~25.04
Independent Director
Patrick Holt
Member of the Audit Committee Independent Director
22.04~25.04

Board activities

Date · Agenda
Date
Agenda
STATUS
ATTN
2023.12.22
Agenda 1 : Cancellation of Treasury Shares
Approved
4/7
2023.11.13
Report 1 : Report of the Year 2023 3Q Financial Statement
Agenda 1 : Treasury Stock Acquisition Trust Agreement
Reported
Approved
6/7
6/7
2023.09.08
Agenda 1 : Stock Acquisition Agreement for subsidiary Hugel America
Agenda 2 : Monetary Loan to subsidiary Hugel America
Approved
Approved
7/7
7/7
2023.08.09
Report 1 : Report of the Year 2023 2Q Financial Statement
Agenda 1 : Appointment of executive officers
Agenda 2 : Appointment of Representative Executive Officer
Reported
Approved
Approved
5/7
5/7
5/7
2023.07.14
Agenda 1 : Proposal to extend the maturity and conversion period of the 2nd unsecured private convertible bonds
Approved
4/7
2023.07.05
Agenda 1 : Proposal to convene a meeting of bondholders for the 2nd unsecured private convertible bonds
Approved
4/7
2023.05.09
Report 1 : Report of the Year 2023 1Q  Business Performance
Report 2 : Report of the Year 2023 1Q Financial Statement
Reported
Reported
7/7
7/7
2023.03.30
Agenda 1 : Appointment of  Chairman of the Board
Agenda 2 : Approval for granting stock purchase options
Agenda 3 : Approval of large-scale internal transactions
Agenda 4 : Proposal for cancellation of the grant of stock purchase options
Approved
Approved
Approved
Approved
7/7
7/7
7/7
7/7
2023.03.09
Report 1 : Report of internal accounting management system evaluation by the Audit Committee
Report 2 : Submission of the audit report for the 22nd term (2022.01.01~2022.12.31) by the Audit Committee
Agenda 1: Proposal to convene the 22nd regular shareholders' meeting
Agenda 2 : Appointment of Executive Officers
Agenda 3 : Proposal for investment in Hugel America
Agenda 4 : Proposal for the method of exercising stock purchase options
Reported
Reported
Approved
Approved
Approved
Approved
7/7
7/7
7/7
7/7
7/7
7/7
2023.02.14
Report 1 : Report of the evaluation of the internal accounting management system
Report 2 : Report of the evaluation of the compliance control system
Report 3 : Report of the subsidiary's delegated decision-making policy
Report 4 : Report of the 2022 KPI performance and 2023 goals
Agenda 1 : Approval of the 22nd (2022.01.01~2022.12.31) Financial Statement
Agenda 2 : Approval of the 22nd (2022.01.01~2022.12.31) Business Report
Agenda 3 : Approval of the 2023 business plan
Agenda 4 : Treasury Stock Acquisition Trust Agreement
Agenda 5 : Approval of the 2023 occupational safety and health business plan
Reported
Reported
Reported
Reported
Approved
Approved
Approved
Approved
Approved
7/7
7/7
7/7
7/7
7/7
7/7
7/7
7/7
7/7
Date · Agenda
Date
Agenda
STATUS
ATTN
2022.11.09
Report 1 : Progress schedule of investment in Hugel America
Agenda 1 : Proposal for the establishment and investment in overseas subsidiaries
Agenda 2 : Approval of concurrent directorship
Agenda 3 : Approval of the grant of stock purchase options
Agenda 4 : Approval of large-scale internal transactions
Agenda 5 : Cancellation of the grant of stock purchase options
Agenda 6 : Termination of the Meditech business
Reported
Approved
Approved
Approved
Approved
Approved
Approved
7/7
7/7
7/7
7/7
7/7
7/7
7/7
2022.09.20
Agenda 1 : Proposal to set the record date for the extraordinary shareholders' meeting
Agenda 2 : Proposal to convene the extraordinary shareholders' meeting
Agenda 3 : Treasury Stock Acquisition Trust Agreement extension
Approved
Approved
Approved
7/7
7/7
7/7
2022.08.10
Report 1 : Progress schedule for the approval of granting stock purchase options
Reported
7/7
2022.07.01
Agenda 1 : Appointment of  Chairman of the Board
Approved
7/7
2022.05.19
Agenda 1 : Proposal to convene the extraordinary shareholders' meeting
Agenda 2 : Proposal for setting the record date
Agenda 3 : Approval of adopting electronic voting
Approved
Approved
Approved
7/7
7/7
7/7
2022.04.14
Agenda 1 : Proposal to convene the extraordinary shareholders' meeting
Agenda 2 : Proposal for the division and purchase of convertible bonds
Approved
Approved
5/6
5/6
2022.04.07
Agenda 1 : Treasury Stock Acquisition Trust Agreement
Approved
5/6
2022.03.08
Report 1 : Report of internal accounting management system evaluation by the Audit Committee
Report 2 : Submission of the audit report for the 21st term (2021.01.01~2021.12.31) by the Audit Committee
Agenda 1 : Amendment of executive compensation regulations
Agenda 2 : Amendment of executive severance
Agenda 3 : Proposal to convene the 21st regular shareholders' meeting
Agenda 4 : Proposal to amend the record date for the extraordinary shareholders' meeting
Agenda 5 : Cancellation of granting stock purchase options
Reported
Reported
Approved
Approved
Approved
Approved
Approved
6/7
6/7
6/7
6/7
6/7
6/7
6/7
2022.02.10
Report 1 : Report of internal accounting management system evaluation
Agenda 1 : Approval of the 21st(2021.01.01~2021.12.31) Financial Statement
Agenda 2 : Approval of the 21st(2021.01.01~2021.12.31) Business Report
Agenda 3 : Liquidation of the Weihai Subsidiary
Agenda 4 : Liquidation of the Vietnam Subsidiary
Reported
Approved
Approved
Approved
Approved
6/7
6/7
6/7
6/7
6/7
2022.01.17
Agenda 1 : Proposal to set the record date for the extraordinary shareholders' meeting
Approved
7/7
Date · Agenda
DATE
AGENDA
STATUS
ATTN
2021.12.16
Agenda 1 : Proposal for setting the dividend record date
Approved
7/7
2021.12.13
Agenda 1 : Treasury Stock Acquisition Trust Agreement
Agenda 2 : Cancellation of Treasury Shares
Approved
Approved
6/7
6/7
2021.10.01
Agenda 1 : Proposal to set the record date for the extraordinary shareholders' meeting
Approved
6/7
2021.09.09
Agenda 1 : Treasury Stock Acquisition Trust Agreement extension
Approved
5/7
2021.04.08
Agenda 1 : Proposal for the method of exercising stock purchase options
Agenda 2 : Proposal for the transfer and cancellation/settlement of real estate contracts
Approved
Approved
7/7
7/7
2021.03.26
Agenda 1 : Reappointment of Co-Chairs of the Board
Agenda 2 : Appointment of Executive Directors
Approved
Approved
7/7
7/7
2021.03.10
Report 1 : Report of internal accounting management system evaluation by the Audit Committee
Report 2 : Submission of the audit report for the 20th term by the Audit Committee
Agenda 1 : Treasury Stock Acquisition Trust Agreement
Reported
Reported
Approved
7/7
7/7
7/7
2021.02.09
Report 1 : Report of internal accounting management system evaluation
Agenda 1 : Approval of the 20th (2020.01.01~2020.12.31) Financial Statement
Agenda 2 : Approval of the 20th (2020.01.01~2020.12.31) Business Report
Agenda 3 : Proposal to convene the 20th regular shareholders' meeting
Agenda 4 : Establishment of  the Compliance Control System
Agenda 5 : Appointment of Compliance Support Personnel
Reported
Approved
Approved
Approved
Approved
Approved
7/7
7/7
7/7
7/7
7/7
7/7

Audit Committee

Hugel has established and operates an audit committee in accordance with Article 41-2 of its Articles of Incorporation. As of the end of December 2022, the audit committee consists of three members, including two outside directors and one non-executive director. The members of the audit committee attend board meetings to independently supervise the directors' duties and may request relevant departments to submit related ledgers and documents in relation to their duties. Additionally, they may receive reports on business matters from the company when necessary and have access to management information through appropriate means.

Title · Name
Careers
Relationships with Shareholders
Term
TITLE · NAME · Careers · TERM
Audit Committee Chair
Seungmin Chee
• Ph.D. in Business Administration from the University of California at Berkeley
• Assistant Professor at the University of Oregon, Eugene
• Member of the Accounting System Deliberation Committee of the Securities and Futures Commission
• Non-executive Director at Korea Institute of Marine Science & Technology Promotion
• Associate Professor at  Korea University Business School
• Certified Public Accountant
- Certified Public Accountant, Deloitte Anjin Accounting Corporation (98.11~00.04, 03.02~03.09)
- Academic Director, Korean Accounting Association (2016~2017, 2018~2019)
- Editorial Board Member, Korean Accounting Association (2020-2021)
- Editorial Board Member, Korean Securities Association (2021-present)
None
22.04~25.04
Audit Committee Member
Patrick Holt
• Bachelor's degree in Biochemistry from Monash University
• President Director, Merck & Co., Inc.
• Vice President, Allergan Inc.
• Non-Executive Director, Ascenda Loyalty
• President, Cordis(Cardinal Health Inc.)
None
22.04~25.04
Audit Committee Member
Taehyoung Lee
• University of Washington MBA
• CEO, Incheon Total Energy Company
• Executive Vice President and Head of the Management Planning Division, GS Energy Co., Ltd.
• CFO, PM Team Leader, and Executive Vice President, GS Corporation
None
22.04~25.04
DATE · AGENDA
DATE
Agenda
STATUS
2023.02.14
Report 1 : Report of internal accounting management system evaluation
Report 2 : Approval of the 22nd (2022.01.01~2022.12.31) Financial Statement
Report 3 : Approval of the 22nd (2022.01.01~2022.12.31) Business Report
Report 4 : Report of the periodic auditor designation results by external auditors
Reported
Reported
Reported
Reported
2023.03.08
Report 1 : Report of internal accounting management system plan for 2023
Agenda 1 : Approval of the internal accounting management system evaluation
Agenda 2 : Submission of the Audit Committee's opinion on internal monitoring mechanisms
Agenda 3 : Confirmation of the audit report for the 22nd term (2022 fiscal year) by the Audit Committee
Agenda 4 : Review of the legality of agendas and documents to be submitted to the 22nd regular shareholders' meeting
Reported
Approved
Approved
Approved
Approved
2023.05.09
Agenda 1 : Approval of the Year 2023 1Q Financial Statement
Approved
2023.08.08
Report 1 : Improvement measures of accounting system of the Financial Services Commission
Agenda 1 : Approval of the Year 2023 2Q Financial Statement
Reported
Approved
2023.11.07
Report 1 : Report of the management issues for the third quarter
Agenda 1 : Approval of the Year 2023 3Q Financial Statement
Reported
Approved

Shareholders' Meeting

2024

DATE
AGENDA
STATUS
DATE · AGENDA
The 23rd Annual Meeting of Shareholders (2024.03.29)
1. Approval of the 23rd financial statements
2. Appointment of Directors (1 Non-Executive Director)
3. Approval of director remuneration limit
Approved
Approved
Approved

2023

DATE
AGENDA
STATUS
DATE · AGENDA
The 22nd Annual Meeting of Shareholders (2023.03.30)
1. Approval of the 22nd Financial Statement
2. Appointment of Directors (1 Non-Executive Director)
3. Approval of granting stock options
4. Approval of director remuneration limit
Approved
Approved
Approved
Approved

2022

DATE · AGENDA
DATE
AGENDA
STATUS
The 21st Annual Shareholders’ Meeting (2022.03.25)
1. Approval of the 21st Financial Statement
2. Approval of director remuneration limit
3. Amendment of executive severance
Approved
Approved
Approved
The 22nd Extraordinary Shareholders' Meeting (2022.04.29)
1. Appointment of Directors (4 Non-Executive Directors, 1 Independent Director)
2. Appointment of independent director, Seungmin Chee to a member of the Audit Committee
3. Appointment of the Audit Committee members
Approved
Approved
Approved
The 22nd Extraordinary Shareholders' Meeting (2022.06.29)
1. Appointment of Directors (1 Non-Executive Director)

Approved

The 22nd Extraordinary Shareholders' Meeting (2022.10.28)
1. Amendment of Articles of Incorporation
2. Approval of granting stock purchase options
Approved
Approved